Abstract OT2-06-01: Highly innovative personalized RNA-immunotherapy for patients with triple negative breast cancer
M Schmidt(Uppsala University Hospital), Uğur Şahin(Johannes Gutenberg University Mainz), J Gruetzner(Uppsala University Hospital), Daniël Langer(The Task Force for Global Health), Oezlem Tuereci(Uppsala University Hospital), Stefanie Bolte(BioNTech (Germany)), Ludwig Heesen(Uppsala University Hospital), Alyssa Klein(Stanford Medicine), Katrin Frenzel(Uppsala University Hospital), Evelyna Derhovanessian(University of Tübingen), Henrik Lindman(Uppsala University), Martin Löewer(Uppsala University Hospital), Valesca Bukur(Uppsala University Hospital), Mustafa Diken, Andreas N. Kuhn(Uppsala University Hospital), Andreas Schneeweiß(German Cancer Research Center), Sebastian Kreiter(Johannes Gutenberg University Mainz)
Cited by 10
Related Papers
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
|New England Journal of Medicine|2020|15.7k
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
|New England Journal of Medicine|2020|2.7k
mRNA-based therapeutics — developing a new class of drugs
|Nature Reviews Drug Discovery|2014|2.4k
Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults
|Nature|2020|1.6k